Objective. The objective of this study was to determine if there is consistent evidence for smoking to be considered a red flag for development of opioid dependence during opioid exposure in patients with pain and chronic pain patients (CPPs).
Introduction
The Tobacco Supplement to the National Comorbidity Survey has determined that the lifetime prevalence for nicotine dependence in the United States is 24% [1] , while 15% are thought to be currently nicotine dependent [2] . These figures, however, do not apply to alcoholics and drug-dependent individuals. Over 90% of alcoholic inpatients are smokers [3] and alcoholism is estimated to be 10 times more common in smokers vs nonsmokers [4] . When formal criteria are applied to these groups, it has been reported that 34% of individuals with alcohol disorders [5] and 52% with substance use disorders [6] meet the full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-4) criteria for nicotine dependence. As such, the association between alcoholism and other substance use disorders and smoking is welldocumented and accepted [7] [8] [9] [10] .
Early research [8, 11] also indicated that there was a very high prevalence of smoking within opioid-dependent individuals who were on methadone maintenance treatment [12] [13] [14] . More than 80% of these opioid-dependent patients smoke [8] . Among these individuals, cigarette smoking is associated with illicit substance use, particularly cocaine use. More interestingly, methadonemaintained patients who reduce their tobacco use reduce cocaine use [15] . Also, methadone-maintained patients who successfully quit smoking are three times more likely not to use cocaine vs smoking peers [16] . Finally, illicit substance use measured through urine toxicology increases in a stepwise fashion from methadonemaintained nonsmoking individuals to smoking chippers (smokers without objective signs of dependence) to heavy smokers [17] . As such, associations among alcoholism and other substance use disorders and smoking are well-documented. For example, analysis of the 1989 National Alcohol and Drug Use Survey from a Canadian database has demonstrated that a positive response to the question "Have you ever smoked cigarettes?" correctly classified 76% of substance abusers [18] . At issue then is whether these smoking research findings apply to patients with pain and chronic pain patients (CPPs) and whether within these groups smoking should be considered a potential red flag for development of opioid dependence on opioid exposure.
In 2007, Fishbain et al. [19] reported that current smoking status in CPPs was predicted by current alcohol-abuse dependence and that smoking up to one pack per day was also predicted by current alcohol-abuse dependence. Additionally, current smokers were more likely to have a current Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III-R) diagnosis of substance use for alcohol, cannabis, amphetamines, or cocaine, but not opioid-abuse dependence [19] . These findings, except for opioid-abuse dependence, fit in well with the findings from the above dependence literature on the association between smoking and alcoholism and illicit drugs. In the same year, Dhingra and Passik [20] in a narrative review raised the issue of whether smoking in CPPs is associated with aberrant drug-taking behaviors (ADTBs). Here, they reviewed five studies [13, 18, [21] [22] [23] , of which one [23] addressed ADTBs. They concluded that smokers are at higher risk for ADTBs on opioid therapy compared with nonsmokers. Since that narrative review, there have been a significant number of studies that have been added to the literature, which have addressed the association of smoking in patients with pain or CPPs and opioid use through a number of different questions. These are the following: 1) Are patients with pain or CPPs who smoke significantly more likely to use opioids vs nonsmoking comparators? 2) Are patients with pain or CPPs who smoke more likely to require more opioids for pain than nonsmoking comparators? 3) Are CPPs who smoke more likely to be drug-alcohol dependent than nonsmoking comparators? and 4) Are patients with pain or CPPs who smoke more likely to demonstrate ADTBs on opioids vs nonsmoking comparators? It is the objective of this evidence-based structured review (described below) to review these four lines of evidence utilizing the type of evidence, strength, and consistency of evidence guidelines [24] . These guidelines are presented in Table 1 . It is hoped that this approach can add to the information available as to whether smoking should be considered a red flag for potential opioid-dependence development on opioid exposure.
Methods
Relevant references were located by the following procedure. MEDLINE, Embase, AMED, Psychological Abstracts, Science Citation Index, and the National Library of Medicine Physician Data Query databases were reviewed utilizing the following subject headings: pain, chronic pain, CPPs, alcohol abuse, alcohol dependence, alcoholism, cannabis abuse, cannabis dependence, cocaine abuse, cocaine dependence, illicit drug abuse, illicit drug dependence, addiction, aberrant drug-related behaviors, ADTBs, opioid abuse, opioid dependence, heroin dependence, methamphetamine abuse, methamphetamine dependence, and addiction. Each of these was sequentially exploded with the medical subject headings smoking and nicotine. Each term was exploded for Pain 1981 Pain , 1984 Pain , 1987 Pain , 1990 Pain , 1993 Pain , 1996 Pain , 1999 Pain , 2002 Pain , 2005 Pain , 2008 . These researchers developed and tested a list of 23 criteria to be used to assess methodological quality of prospective, historical cohort, and case-control studies. For details of how these criteria were developed, the reader is referred to the original studies [38, 39] . Ten criteria were selected from their list, which were appropriate to the studies utilized (Table A5 ). The other 13 criteria addressed randomized trials and were therefore not appropriate to the reviewed studies. In addition to the selected criteria, three criteria (positive if the data were collected by means of a standardized method of acceptable quality to measure smoking, dependence, and ADTBs) were added for the quality analysis of each study. This resulted in a total of 13 criteria. For each included study, each criterion was rated either present/fulfilled (+), not present/unfulfilled (-), or not applicable (NA). NA was used as follows. There were basically four types of studies analyzed for quality: case-control, cohort, correlational, and case series. Thus, some criteria in Appendix Table A5 pertained only to case-control studies, while others applied only to cohort studies, etc. As such, NA was used if the criterion in question pertained to another type of study other than the one being reviewed. In addition, NA was used when that criterion did not pertain to the study in question. NA was not used when information was not available or not described [40] . Under those circumstances, a negative was assigned [40] . A negative was also assigned if the item did not meet the preselected criteria [40] . Each study was rated independently for each criterion by the senior author (DAF) and another author (BC). Both raters chose either a positive, negative, or NA for each criterion for each study selected for detailed review. The assigned categorizations by DAF and BC for each study were then compared in a meeting. Any discrepancies in the categorizations were resolved by mutual agreement. This resulted in a final decision as to whether each criterion received a negative, positive, or NA categorization. Categorizations were then summarized and placed into tabular format (Table A5 ). A quality score was obtained by counting the number of positives obtained. This score was divided by 13 (the total number of criteria) minus the number of NAs and multiplied by 100, which gave the percentage quality score.
Studies scoring less than 50% historically have been rated as "low quality" [40] . These studies are usually not utilized to arrive at conclusions about a review topic. For the purposes of this review, we arbitrarily set the acceptable quality score at 60% in order to avoid marginal studies. Studies scoring less than 60% were then not utilized at arriving at our conclusions.
The senior author was the one who independently abstracted the data into Tables A1-A4 . However, data abstraction was checked independently by BC. Any discrepancies in this classification were also resolved by mutual agreement. In addition, BC checked the classifications of the reviewed studies, that is, whether the reviewed study was a cohort, case-control, etc. Any discrepancies in this classification were also resolved by mutual agreement.
The categorization of the type of evidence the study represented was based on the guidelines developed by the Agency for Health Care Policy and Research (AHCPR) for categorizing the levels of evidence represented by reviewed studies (Table 1 , Evidence Guidelines subsection I) [24] . Studies were categorized I through V according to this scheme. This categorization was also independently arrived at by the senior author and BC. Any discrepancies were again resolved by mutual agreement in a meeting format.
The strength and consistency of the research evidence for each study grouping (Tables A1-A4 ) was then rated according to the AHCPR consistency of evidence guidelines [24] developed for this purpose (Table 1 , subsection II). These guidelines allow the researcher to categorize the reviewed evidence as being consistent, generally consistent, inconsistent, or demonstrating little or no evidence for supporting the hypothesis under study. The hypotheses from the four lines of evidence in this review were the following: 1) patients with pain or CPPs who smoke will be more likely to be on opioids vs their nonsmoking counterparts; 2) patients with pain or CPPs who smoke will be more likely to use larger quantities of opioids vs their nonsmoking counterparts; 3) CPPs who smoke will be more likely to be diagnosed with substance dependence/ addiction vs their nonsmoking counterparts; and 4) patients with pain or CPPs who smoke will be more likely to demonstrate ADTBs vs their nonsmoking counterparts. In using the consistency rating guidelines, only studies attaining a score of 60% or greater were used. Ratings according to these guidelines (Table 1) were performed independently by the senior author and BC. Any discrepancies were later resolved by mutual agreement.
Finally, the data from Tables A1-A4 were placed into a  summary table (Table 2 ). This table was designed to summarize the overall findings of the structured review for each hypothesis. It has the following headings: hypothesis, number of studies, % of studies by type of evidence, average quality score for the group, % of all studies supporting the hypothesis, and strength/consistency of the findings for the hypothesis (according to the AHCPR guidelines in Table 1 [24]).
Results
Six studies addressed the hypothesis that pain patients/ CPPs who smoke are significantly more likely to use opioids vs nonsmoking comparators (Table 2) . Of these studies, 50% were type 3 and 50% were type 4. Average quality score was 85.4%. Here, 100% of the studies found that patients with pain or CPPs who smoke are significantly more likely to use opioids. The strength/consistency of this evidence was rated as A (Table 1) .
Three studies addressed the hypothesis that patients with pain or CPPs who smoke are significantly more likely to require more opioids for pain than nonsmoking comparators (Table 2) . Of these studies, 100% were type 4. Average quality score was 87.8%. Here, 100% of the studies found that patients with pain or CPPs who smoke are significantly more likely to use more opioids for pain than nonsmoking comparators. The strength/consistency of this evidence was rated as B (Table 1) as there were only three studies.
Three studies addressed the hypothesis that CPPs who smoke are more likely to be diagnosed with drug dependence vs their nonsmoking counterparts (Table 2) . Of these studies, 66.6% were type 3 and 33.3% were type 4. Table 1 Patients with pain or CPPs who smoke are significantly more likely to be on opioids vs nonsmoking counterparts. Average quality score was 86.9%. Here, 100% of the studies found that CPPs who smoke are more likely to be diagnosed with drug dependence vs their nonsmoking counterparts. The strength and consistency of this evidence was rated as B (Table 1) as there were only three studies.
Three studies addressed the hypothesis that patients with pain or CPPs who smoke are more likely to demonstrate ADTBs vs their nonsmoking counterparts (Table 2) . Of these studies, 66.6% were type 3 and 33.3% were type 4. Average quality score was 80.6%. Here, 100% of the studies found that patients with pain or CPPs who smoke were more likely to demonstrate ADTBs vs nonsmoking counterparts. The strength/ consistency of this evidence was rated as B (Table 1) as there were only three studies.
Overall, 46.6% of the 15 studies utilized in this evidencebased structured review (Table 2) were type 3 and 53.4% were type 4 ( Table 1) . Of the 15 studies, none had quality scores below 60% and therefore all studies were all in the strength/consistency ratings. The overall average quality score for the 15 studies was 85.3%. A total of 100% of the studies in each grouping supported the hypothesis for that grouping. Overall, this led to one A (consistent multiple studies) and three B (generally consistent) consistency ratings ( Table 2) .
Discussion
This evidenced-based structured review has attempted to answer the question of whether there is evidence in patients with pain or CPPs that smoking should be considered a potential red flag for development of dependence on opioids on opioid exposure. To that end, this review has examined four lines of evidence: Are patients with pain or CPPs who smoke more likely to use opioids vs nonsmoking counterparts? Are patients with pain or CPPs who smoke more likely to require more opioids vs nonsmoking counterparts? Are CPPs who smoke more likely to be drug-alcohol dependent vs nonsmoking counterparts? And are patients with pain or CPPs who smoke more likely to demonstrate ADTBs vs nonsmoking counterparts? In each line of evidence, 100% of the studies indicated that smokers differ from nonsmokers for the hypothesis derived from that line of evidence (Table 2 ). This generated high consistency scores (A's and B's) for each hypothesis. Overall, therefore, there is limited indirect evidence that smoking may be a red flag for potential opioid-dependence development on opioid exposure.
However, although these lines of evidence are extremely consistent, at issue is whether they can be utilized as proof for potential opioid-dependence development on opioid exposure or whether they represent other pro- [20] . As such, the strongest line of evidence for smoking being a red flag for potential opioiddependence development on opioid exposure rests with the third line of evidence where there are currently only three studies.
Additional evidence that speaks to the question raised by this review and not presented in Tables A1-A4 as it did not come from pain studies relates to genetic and neurophysiological studies in humans. Here, the evidence is as follows. Alcohol dependence and habitual smoking co-occur and this co-occurrence is transmitted within families, which has been well-established through adoption, twin, and family studies [57] . Several DNA regions have been identified, which may contain genes that confer susceptibility to alcoholism and risk for habitual smoking [58] [59] [60] . Recent neurophysiological studies have found a direct overlap between nicotine, alcohol, and cocaine cuereactivity in the ventral striatum for self-reported craving for these drugs [61] . Finally, there is a significant evidence that nicotine is involved in the development of other drug dependencies and that development of dependence to nicotine generally precedes development of dependence on alcohol and illicit drugs [10] . Nicotine has thus been identified as a "gateway drug" to other dependencies [10] . It also appears that people who never smoked rarely abuse alcohol or illicit drugs [10] . Overall, these nonpain studies indicate that patients with pain or CPPs who smoke should be at higher risk than nonsmoking counterparts for development of dependence on opioids if so exposed.
What are the possible confounders to the results of this review? The first major confounder is how smoking is defined. A review of the studies included in Tables A1-A4 indicated that studies generally differ on how they define smoking/nonsmoking. Here, smoking has been defined as heavy, light [62] , intermittent [62] , greater than one pack per day, some day smokers, less than one pack per day, etc. In addition, some studies looked at and included former smokers [63] . These different categories make it difficult to compare studies and could serve as sources of confounding in the actual studies. Another issue here is how to treat the concept of nicotine dependence [64] . None of the reviewed studies utilized this concept. It is also unclear as to which of the terms utilized for smokers (above) translates into actual nicotine dependence, which is highly heritable [7] . The closest probably would be smoking one pack or greater per day. This translation is important because it is likely that it is the heavy smoker who actually fulfills the diagnostic criteria for nicotine dependence [64] . This is the smoker who would be at greatest risk for opioid dependence on opioid exposure.
The second major potential confounder to the results of this review is depression. It appears that persons with depression are more likely to be smokers, to be dependent smokers, and to have difficulty stopping smoking [65] . None of the studies in Tables A1-A4 controlled for depression, except for Fishbain et al. [19] . As such, this omission could have served as a potential confounder in these studies and thus could have impacted on the results of this review.
What are the implications for the pain clinician from the findings of this evidence-based structured review (there is limited indirect evidence that smoking may be a red flag for potential opioid-dependence development on opioid exposure)? The major implication is that pain clinicians when evaluating CPPs for possible chronic opioid maintenance should begin to pay attention to and document the CPP's past and present smoking status. Presently, as demonstrated in this review, there are few prospective studies that address the problem studied in this review. As such, it is the opinion of this research group that a finding of past or current smoking should not necessarily preclude that CPP from chronic opioid maintenance. However, these patients should be perceived as potentially being at greater risk than nonsmoking CPPs for development of opioid dependence on opioid exposure, and if placed on opioids, they should be monitored closely for ADTBs. CPPs who are smoking one pack or greater should be monitored even more closely as these smoking levels are likely to indicate significant nicotine dependence, which, as pointed out, is highly heri- 
